Our Team
Since our inception in 2012, Lipodystrophy United has made accomplishments that have helped to build a supportive community of patients, improve the understanding of the burden of living with lipodystrophy, and expand awareness.
Andra Stratton
Co-Founder, Board Advisor, Board Member
As a mother, a patient, and the co-founder and President of Lipodystrophy United, my journey represents just one among many who live with Lipodystrophy (LD), each story unique in subtype and severity.
Following a 37-year diagnostic odyssey, I was finally diagnosed with Familial Partial Lipodystrophy. Despite sensing something was different about my body and experiencing numerous health issues throughout my life, obtaining a diagnosis was a long and challenging process. My journey revealed the root cause behind years of high cholesterol, diabetes, high blood pressure, and relentless hunger beyond what most could comprehend. Living with LD means facing constant judgment and scrutiny due to my visibly distinct appearance. While some may perceive it as a blessing to lack cellulite, the reality is far from glamorous, marked by daily medications, restricted diets, and a myriad of health complications. Despite the outward appearance of health, the progressive nature of LD brings progressive multi-system disease as well as challenges in being taken seriously by others. However, finding a diagnosis has empowered me to advocate for myself and others affected by LD.
While treatments and a cure remain elusive, I am grateful to work alongside inspiring patients, doctors, and researchers worldwide, striving to improve outcomes and pave a smoother path for those navigating the complexities of LD. Despite the hardships, I count myself fortunate for the opportunity to make a difference in the lives of others facing similar challenges.
Contact: an***@*****************ed.org
Larry Seida
Board President and Chief Financial Officer
Larry Seida graduated from the University of Minnesota in 1986 with a Bachelor of Science in Software Engineering. He began his career in the telecommunications industry, designing software systems for six years before transitioning into entrepreneurship alongside his father in the automotive repair industry. Together, they expanded their single-location body shop into a thriving nine-location operation employing more than 110 people. During this period of growth, he developed expertise in business management, financial oversight, and operational leadership. In 2015, they successfully sold the company to a national consolidator, and he retired the following year. In 2021, his family’s path changed when one of his sons was diagnosed with lipodystrophy. As they navigated this rare disease journey, his wife became involved with Lipodystrophy United.
As LU was growing, the organization needed someone with business and financial experience, and he eagerly volunteered to help. Today, he is committed to applying his professional background to strengthen the organization’s operations and advance its mission. Through advocacy, stewardship, and community engagement, he hopes to contribute in a meaningful way to improve the lives and wellbeing of those affected by lipodystrophy and all of the warriors in the rare disease community.
Contact: la*********@*****************ed.org
Kate Stratton
Executive Director
My name is Kate Stratton, and I am deeply passionate about advancing the health and well-being of all people. I currently serve as the Executive Director of Lipodystrophy United, where I lead with a strong commitment to patient advocacy, community-building, and collaborative research.
This work is deeply personal to me. My mother, who lives with lipodystrophy, co-founded Lipodystrophy United. Growing up alongside her, I saw firsthand the challenges of living with a rare disease, and the transformational power of advocacy. Her active engagement with the lipodystrophy community empowered her and ability to communicate the burden of the disease, showing me the critical role patients play in shaping progress.
Over the past two years, I’ve focused on strengthening our community and expanding our impact. I’ve launched new programs like Tea with LU, a virtual support space for patients and caregivers; co-led an international research symposium in partnership with the University of Michigan; received two certifications in patient advocacy with the Professional Patient Advocates in Life Sciences (PPALS); and grown our internal team. I’ve built strong collaborations with global lipodystrophy foundation partners and worked alongside clinicians, researchers, and industry leaders to ensure patients are heard, supported, and included. I helped lead our successful presence at ENDO two years in a row, where we educated hundreds of clinicians about lipodystrophy.
My mission as ED is to bridge the gap between lived patient experience and decision-making in research, treatment, and policy. I strive to center patient voices in every aspect of our work, from clinical trial design to public awareness, while fostering a compassionate, resilient, and united community.
Looking ahead, I am committed to continuing my work as a public health leader to ensure that all people living with lipodystrophy receive accurate diagnoses, high-quality care, effective treatments, and, one day, a cure.
Contact: ka**@*****************ed.org
Francesca Amato
Operations Manager
In May 2024, I graduated from the University of Miami, Florida, with a degree in psychology and minors in biology and anthropology. I developed a deep passion for public health and patient advocacy throughout my studies. Early on, I realized that patients are often dehumanized and reduced to their diagnoses. Frequently receiving treatment that focuses solely on physical symptoms. This approach often overlooked that they were humans and should be treated as such.
Growing up, one of my closest friends worked for a rare disease foundation after losing a family member to the condition. It wasn’t until years later that I learned several people close to me, including one of my best friends, were also affected by this same “rare” disease. Through my friends, I came to understand that the lack of awareness surrounding rare diseases often leaves individuals feeling isolated and more “rare” than they truly are.
Witnessing the positive impact of organizations like Lipodystrophy United, I was excited to have the opportunity to work with them. I am committed to broadening awareness and changing how healthcare views and treats those in the rare disease community.
Contact: fr*******@*****************ed.org
Trey Naese
2026 Summer Intern
I am a rising junior at the University of Notre Dame, majoring in Biological Sciences with a minor in Science and Patient Advocacy. As an aspiring doctor, I hope to gain a better understanding of the field of medicine from the patient perspective. This summer, I am thrilled to be working with Lipodystrophy United on various advocacy projects, especially preparing for the EL-PFDD meeting. I am passionate about hearing patient stories and turning them into tangible impact. Through this experience, I hope to gain a greater understanding of the challenges faced by individuals living with rare diseases. Ultimately, it is through this understanding that I aspire to bridge gaps among patients, doctors, researchers, and legislators to promote meaningful change in the healthcare industry.
Stephanie Fischer
Board Member
Stephanie Fischer is a rare disease patient and stroke survivor who serves on the Pennsylvania Rare Disease Advisory Council. She has patient advocacy experience with industry and non profit organizations including the MPN Research Foundation and the EveryLife Foundation for Rare Diseases. Stephanie previously spent more than 10 years focused on health policy communication at the Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) after working on Capitol Hill for Congressman Jim Greenwood. She is passionate about empowering patients and caregivers/care partners to engage with policymakers and the biopharmaceutical industry.
Ben Dickerson
Board Member
Ben Dickerson is a market farmer in Corrales, New Mexico, with deep roots in community systems and food and health equity. He holds an MFA in Poetry from the New School and brings diverse experience spanning retail management and executive leadership in the sustainability sector. Ben’s commitment to Lipodystrophy United is deeply personal. His sister struggled with undiagnosed lipodystrophy into her 30s before founding the organization to build community and provide resources that were previously inaccessible to patients and families navigating this rare condition.
Abbey Hauser
Board Member
Abbey Hauser is a rare disease advocate with a passion for health equity as it relates to rare disease and chronic illnesses. Their work draws on years of experience in various roles at rare disease patient advocacy groups. Abbey enjoys helping advocates tell their stories and connecting it to policy at an accessible level. They are also a speaker who has shared often about the transition of health care from pediatrics to adulthood, sharing your story, and adaptive sports. When not advocating, Abbey loves adaptive sports like nordic sit skiing and wheelchair tennis, reading, writing poetry, collecting stamps, and sending cards to friends.
Mandy Pulliam
Board Member
Mandy is a senior executive with 15+ years of diverse and extensive leadership experience across industry and academic medical centers, and also a person living with lipodystrophy. Valued as a strategic thinker with a proven ability to lead cross-functional teams, develop talent and influence and inspire team members at all levels of the organization. Expert in building team consensus for strategic direction, evaluating and executing challenging decisions in crisis situations, and developing new paradigms for clinical research. Strong healthcare services professional skilled in Pelvic Reconstructive Surgery, Healthcare Management, Healthcare, Clinical Research, and Medical Education.
Dena Winchester
Board Member
Dena Winchester is a genetic counselor with lipodystrophy. After being diagnosed with
generalized lipodystrophy at age 11, Dena has been on a mission to spread awareness of
lipodystrophy and support the rare disease community. In high school she maintained a blog
describing her daily life with lipodystrophy, and featured other patient stories in her writings.
Now, Dena works as a genetic counselor specializing in hematology and is dedicated to
promoting patient autonomy and guiding people with rare diseases through the diagnostic
odyssey. She is proud to be a part of the LU and can’t wait to see what the board can
achieve for the LU community!
Elif Oral, MD
Scientific Advisory Board
Dr. Elif Oral is a Professor in the Division of Metabolism, Endocrinology and Diabetes at the
University of Michigan and a clinician-researcher in endocrinology and internal medicine. According to her University of Michigan Health profile, she completed medical school at Istanbul Universitesi in 1992, residency training in internal medicine at Sinai-Grace Hospital of Detroit in 1996, and NIH fellowship training in endocrinology, metabolism, and diabetes in 1999. Her clinical interests include insulin resistance, obesity, lipid disorders, diabetes, atypical diabetes, and rare metabolic and endocrine disorders, including lipodystrophy.
Dr. Oral’s research focuses on adipocytes, leptin, lipid metabolism, obesity, and lipodystrophy, and she is especially known for work demonstrating the effectiveness of leptin in rare lipodystrophy syndromes. Her University of Michigan profile notes that this research helped pave the way for metreleptin approval for lipodystrophy, and that she also directs Michigan’s Atypical Diabetes Program and Obesity and Metabolic Disorders Program.
Her PubMed publications can be viewed here: PubMed publications
Rebecca Brown, MD M.H.Sc
Scientific Advisory Board
Dr. Elif Oral is a Professor in the Division of Metabolism, Endocrinology and Diabetes at the
Dr. Rebecca J. Brown is Co-Chief of the Diabetes, Endocrinology, & Obesity Branch at NIDDK and Chief of the Section on Translational Diabetes and Metabolic Syndromes at the NIH. Her NIDDK biography notes that she earned her M.D. from Mayo Medical School in 2002, completed residency at Rainbow Babies and Children’s Hospital, trained as a fellow at NICHD and NIDDK, earned an M.H.Sc. from Duke University in 2011, and has served as an investigator at NIDDK since 2012.
Dr. Brown’s research focuses on the mechanisms that regulate energy metabolism in humans, using rare diseases as models to better understand both rare and common metabolic conditions. Her group studies disorders of extreme insulin resistance, including lipodystrophy, insulin receptor mutations, and autoimmune conditions affecting insulin signaling, with particular interest in how leptin improves metabolic disease in lipodystrophy.
Her PubMed publications can be viewed here: PubMed publications
Prof. Baris Akinci, MD
Scientific Advisory Board
Prof. Baris Akinci, MD, is a professor in the Division of Endocrinology and Metabolism in the Department of Internal Medicine at Dokuz Eylul University in Izmir, Turkey. He received his M.D. from Ege University and completed both his residency and fellowship at Dokuz Eylul University. His academic and research experience has included work at the University of Leeds in the UK, UT Southwestern Medical Center in the United States, Dokuz Eylul University, and the University of Michigan.
Prof.. Akinci is currently affiliated with the Izmir Biomedicine and Genome Center, where his research focuses on the clinical characteristics and natural history of lipodystrophy, including its relationship to metabolic abnormalities and end-organ complications. He is the founder of the
Turkish Lipodystrophy Study Group and a board member of the European Consortium of Lipodystrophies (ECLip).
His PubMed publications can be viewed here: PubMed publications
Ormond A. MacDougald, PhD
Scientific Advisory Board
Dr. MacDougald is the John A. Faulkner Collegiate Professor of Physiology at the University of Michigan and Professor of Molecular and Integrative Physiology and Internal Medicine. After completing his postdoctoral fellowship in Dan Lane’s lab at Johns Hopkins, he joined the University of Michigan faculty, where he has built a distinguished career in metabolism and adipose tissue research.
Dr.MacDougald’s professional interests focus on all aspects of adipose tissue biology, including how adipocytes develop, function, and communicate with other cell types throughout the body. His University of Michigan profile also highlights his strong commitment to mentoring the next
generation of scientists, along with national recognition for both his research and mentorship.
His PubMed publications can be viewed here: PubMed publications
Lindsay Fourman, MD
Scientific Advisory Board
Dr. Lindsay T. Fourman is an Assistant Professor of Medicine at Harvard Medical School, a board-certified endocrinologist in the Metabolism Unit at Massachusetts General Hospital, and Associate Director of the Lipid and Metabolism Associates Clinic. Her Mass General profiles note that she earned her M.D. from Weill Cornell Medical College and completed both her residency and fellowship training at Massachusetts General Hospital.
Dr. Fourman leads a clinical research program focused on cardiometabolic disease and lipodystrophy. Her work includes an R01-funded clinical trial evaluating tesamorelin, an NIH K23-funded study on the cardiometabolic effects of in utero exposure to maternal infection, site leadership for a metreleptin trial in familial partial lipodystrophy, and leadership of the MGH Lipodystrophy Biorepository (ODYSSEY) and the MGH Metabolic Disorders Conference.
Her PubMed publications can be viewed here: PubMed publications
Stephen I. Stone, MD
Scientific Advisory Board
Dr. Stephen I. Stone, MD, is an Assistant Professor of Pediatrics in the Division of Endocrinology and Diabetes at Washington University School of Medicine in St. Louis and a board-certified pediatric endocrinologist. According to WashU, he earned his medical degree from the Chicago Medical School at Rosalind Franklin University, completed his residency in general pediatrics at the Medical College of Wisconsin, and went on to complete fellowship training in pediatric endocrinology at Washington University. He joined the WashU faculty in 2016.
Dr. Stone’s clinical and research work focuses on rare and genetic forms of diabetes, severe insulin resistance syndromes, and lipodystrophy. His lab integrates clinical research with transgenic and gene-edited models, including CRISPR-based mouse models and patient-derived iPSCs, to study the molecular basis of insulin resistance and support precision medicine approaches for rare endocrine disorders.
His PubMed publications can be viewed here: PubMed publications
Justin Rochford, PhD
Scientific Advisory Board
Professor Justin Rochford leads a research team at the Rowett Institute at the University of Aberdeen, where he studies how fat tissue affects health and disease. His University of Aberdeen profile notes that the Rochford lab is part of the Nutrition, Obesity and Disease theme at the Rowett Institute and the Aberdeen Cardiovascular and Diabetes Centre, with research focused on how dysfunction in adipose tissue contributes to conditions such as type 2 diabetes, liver disease, vascular disease, cancer, and lipodystrophy.
Professor Rochford is particularly known for his work on lipodystrophy, including efforts to understand what goes wrong in fat cells, how adipose dysfunction affects other organs, and how new treatments for lipodystrophy can be developed and tested. His Aberdeen profile also notes his collaborative approach and his roles as an Executive Board Member of the European Consortium for the Study of Lipodystrophies (ECLip) and a Scientific Advisory Board Member for Lipodystrophy United.
His PubMed publications can be viewed here: PubMed publications
Yael Lebenthal, MD
Scientific Advisory Board
Prof. Yael Lebenthal, MD, is Director of the Pediatric Endocrinology and Diabetes Unit at the Dana-Dwek Children’s Hospital at Tel Aviv Sourasky Medical Center (Ichilov). Her official hospital profile notes that she studied medicine at the Hebrew University–Hadassah Medical School in Jerusalem, completed her pediatrics residency at Dana-Dwek Children’s Hospital, and completed fellowship training in pediatric endocrinology at Schneider Children’s Medical Center of Israel.
Prof. Lebenthal is a pediatric endocrinologist and researcher with extensive experience in diabetes, endocrinology, and metabolic disorders in children. Her profile highlights longstanding academic, teaching, and clinical research work, including leadership roles at Ichilov and a large body of scientific publications in pediatric endocrine and metabolic health.
Her PubMedpublications can be viewed here: PubMed publications
Nivedita Patni, MD
Scientific Advisory Board
Dr. Nivedita Patni, MD, is an Associate Professor in the Division of Pediatric Endocrinology at UT Southwestern Medical Center and Program Director of the Pediatric Endocrinology Fellowship. She earned her medical degree from the All India Institute of Medical Sciences in India, completed her pediatrics residency at Miami Children’s Hospital, and then completed fellowship training in pediatric endocrinology at UT Southwestern.
Dr. Patni’s clinical and research work focuses on rare and genetic dyslipidemias, lipodystrophy syndromes, and related metabolic disorders in children. UT Southwestern highlights her work on type 1 hyperlipoproteinemia, novel LMNA-associated lipodystrophy syndromes, and metabolic phenotyping, and her publications include studies on juvenile-onset generalized lipodystrophy and lipodystrophy practice guidelines.
Her PubMed publications can be viewed here: PubMed publications.
Board of Directors
Scientific Advisory Board
Patient Advisory Board
Meet the People Behind Lipodystrophy United
We work every day to better the lives of people living with lipodystrophy. Our efforts to raise funds for expanded research, trial access, community and clinician education are global endeavors that have made an impact on the future of lipodystrophy.
The LU Team
Kate Stratton
Sharon Halperin
Francesca Amato
Trey Naese
Board of Directors
Andra Stratton
Larry Seida
Stephanie Fischer
Ben Dickerson
Abbey Hauser
Mandy Pulliam
Sharon Halperin
Dena Winchester
Scientific Advisory Board
Elif Oral, MD
Rebecca Brown, MD M.H.Sc
Baris Akinci, MD
Ormond A. MacDougald, PhD
Lindsay Fourman, MD
Stephen I. Stone, MD
Justin Rochford, PhD
Yael Lebenthal, MD
Nivedita Patni, MD
Patient Advisory Board
Crystal Chavez
Briana Steiner
Gretchen Young
Jennifer Hepler
Peggy Turbin
Crystal Chavez
Patient Advisory Board
Crystal Chavez is a nursing student and dedicated patient advocate living with familial partial lipodystrophy (FPLD3). As a member of the Patient Advisory Board for Lipodystrophy United, she contributes her lived experience and healthcare perspective to help shape patient-centered programs, support community growth, and raise awareness about rare metabolic diseases. Crystal is passionate about empowering patients and helping bridge the gap between healthcare systems and the real-life challenges of living with a rare condition.
Briana Steiner
Patient Advisory Board
Briana Steiner was diagnosed with Familial Partial Lipodystrophy (FPLD) in 2009 at age 32, beginning her journey in the rare disease community as both patient and advocate. For the past decade, she has served as a leader of Living with Lipodystrophy, including eight years as main administrator, supporting individuals and families affected by all forms of the condition. Briana works to foster education, empowerment, and connection within a safe, supportive community. Her collaboration with Lipodystrophy United reflects her commitment to advocacy, awareness, and ensuring no one faces lipodystrophy alone. She leads with resilience, humor, and unwavering determination.
Gretchen Young
Patient Advisory Board
Gretchen Young is a 50-year-old patient living with Familial Partial Lipodystrophy in the Pittsburgh, Pennsylvania area. She was diagnosed in 2019 at the National Institutes of Health and soon after began participating in clinical research with Dr. Elif Oral at the University of Michigan. Since her diagnosis, Gretchen has actively contributed to the advancement of lipodystrophy research. She has participated in three medication trials, multiple medical equipment and testing studies, and is currently involved in a DNA study focused on atypical diabetes. Gretchen discovered Lipodystrophy United about three years ago and found ameaningful connection with a community that truly understands the challenges of living with this rare condition. As a member of the Patient Advisory Board, she hopes to support and encourage others while helping to improve awareness, research, and patient care for people living with lipodystrophy.
Jennifer Hepler
Patient Advisory Board
Jennifer Hepler is an experienced case manager with a strong commitment to social justice and empowering individuals to reach their full potential. She is passionate about advocating for marginalized communities and amplifying the voices of those often unheard. As someone living with lipodystrophy, she is dedicated to helping and inspiring others to build self-advocacy skills and confidently navigate their needs. She holds a Bachelor of Arts in Criminal Justice and a Master of Public Administration.
Peggy Turbin
Patient Advisory Board
Peggy Turbin’s life’s work has been in educating young children and early childhood education teachers by continuing to grow her own knowledge, skills, and competencies and creating ways to share that with others. It has been 20 years since her FPLD diagnosis, and she is now understanding the importance of participation in the lipodystrophy community. Education through storytelling, sharing, advocacy, and active participation feels very much aligned with her work in education, and she is happy to be able to support LU.
About Us
Dedicated to serving the lipodystrophy community
Our Story
When patients become the experts
Our Path
From then until now – See how far we’ve come!
The News
Check out our recent media appearances
Fostering Unity and Collaboration with Our Dedicated Partners



